Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ABIOMED, Inc. - Common Stock (NQ:ABMD)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 21, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ABIOMED, Inc. - Common Stock

< Previous 1 2 3 Next >
Risk Vs Reward Vs Folly: Navigating Investment Choices
During the dot-com era, many individuals ridiculed Buffett for his refusal to invest in ventures that contradicted his principles. Years later, the majority of these so-called experts, if not all of... 
Via Talk Markets
Is It Too Late to Buy Johnson & Johnson's Stock?
This healthcare juggernaut's recent quarterly results prove just how strong its business is. 
Via The Motley Fool
2 Best Buffett Stocks to Buy for the Long Haul
Both of these stocks look like bargains right now. 
Via The Motley Fool
Interest Rate Hikes Won't Stop These 2 Cash-Rich Growth Stocks
Even if interest rates go up, you likely won't need to worry about these stocks. 
Via The Motley Fool
The Best Stocks to Invest $20,000 in Right Now
The investments you make now could power your portfolio returns for years to come. 
Via The Motley Fool
Warren Buffett Loves These Stocks. Should You Buy Them Before 2023?
There's a lot more ahead for these market giants. 
Via The Motley Fool
If You Invested $100 In This Stock 10 Years Ago, You Would Have $2,800 Today
 
Via Benzinga
Here's How Much You Would Have Made Owning Abiomed Stock In The Last 15 Years
 
Via Benzinga
Will Investors Notice Exciting Sign On Abiomed's Chart?
 
Via Benzinga
Pfizer, Novartis Are Among Overbought Healthcare Stocks: Are They Worth A Look?
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. Here’s the latest list of major overbought players in this sector, with an RSI... 
Via Benzinga
2 Top Dividend Kings to Buy for the Long Haul
No matter how much changes, these two healthcare giants keep performing. 
Via The Motley Fool
This Monster Dividend Stock Isn't Done Growing
Is another deal on the way for Johnson & Johnson? 
Via The Motley Fool
Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sanofi
There are now two companies in the ring for a Horizon takeover. 
Via Investor's Business Daily
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
This space is ripe with opportunities for investors. 
Via The Motley Fool
Beat the Dow Jones With This Unstoppable Dividend Stock
Johnson & Johnson has outperformed the Dow so far this year. 
Via The Motley Fool
Analyst Forecasts $101-117/Share Offer Price For Horizon Therapeutics' Buyout
 
Via Benzinga
Bear Market Blues? 3 of the Best Stocks to Own in 2023
2023 could be a big year for each of these healthcare companies. 
Via The Motley Fool
Peering Into Abiomed's Recent Short Interest
Abiomed's (NASDAQ:ABMD) short percent of float has risen 6.62% since its last report. The company recently reported that it has 2.08 million shares sold short, which is 5.96% of all regular shares that... 
Via Benzinga
2 Warren Buffett Passive Income Stocks You Can Buy to Boost Your Yield
Buffett loves stocks that pay dividends. Is it any wonder Berkshire Hathaway is poised to collect more than $6 billion worth of them next year? 
Via The Motley Fool
Better Buy: Johnson & Johnson vs. Abbott Laboratories
These two healthcare giants are among the safest stocks investors can buy right now. 
Via The Motley Fool
Johnson & Johnson Could Level Up With Its $16.8 Billion Purchase of Abiomed
The company is planting seeds for future growth. 
Via The Motley Fool
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
These robust businesses will be around well beyond the next 10 years. 
Via The Motley Fool
3 No-Brainer Stocks to Buy in a Downturn
These companies thrive when others falter. 
Via The Motley Fool
Johnson & Johnson's Big Purchase, Amazon's New Moves, and More
Plus, we run through some shortcuts that could help you with your financial planning. 
Via The Motley Fool
Is Johnson & Johnson's Purchase of Abiomed Good for Investors?
The $16.6 billion acquisition shakes up MedTech. 
Via The Motley Fool
Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review
A mixed jobs report and heavy earnings swung stocks. 
Via Investor's Business Daily
Here's How Much $100 Invested In Abiomed 20 Years Ago Would Be Worth Today
Abiomed (NASDAQ:ABMD) has outperformed the market over the past 20 years by 18.13% on an annualized basis producing an average annual return of 25.63%. Currently, Abiomed has a market capitalization of... 
Via Benzinga
5 Analysts Have This to Say About Abiomed
Over the past 3 months, 5 analysts have published their opinion on Abiomed (NASDAQ:ABMD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Upgrades 
Via Benzinga
Is Johnson & Johnson an Underrated Growth Stock?
Johnson & Johnson trades at a modest earnings multiple, and it may warrant a premium. 
Via The Motley Fool
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.